SynthesisEuropean archives of psychiatry and clinical neuroscience2009
The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis.
Synthesis in European archives of psychiatry and clinical neuroscience, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03588572 (A Randomized, Single Blind, Controlled, Longitudinal Study of the Effects of Venlafaxine Hydrochloride Capsules on the Language Function of Stroke Patients With Subcortical Aphasia Using fMRI), which is not on this map. Cited by 40 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Single Blind, Controlled, Longitudinal Study of the Effects of Venlafaxine Hydrochloride Capsules on the Language Function of Stroke Patients With Subcortical Aphasia Using fMRI
Who cites it
40 citing papers in PubMed, 6 syntheses or guidelines pooled it, 111 citations in OpenAlex.
- Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.BMC psychiatry · 2023Pooled it
- Evidence-based, pharmacological treatment guideline for depression in Korea, revised edition.Journal of Korean medical science · 2014Guideline
- Quetiapine monotherapy in acute phase for major depressive disorder: a meta-analysis of randomized, placebo-controlled trials.BMC psychiatry · 2012Pooled it
- Depression in adults: drug and physical treatments.BMJ clinical evidence · 2011Pooled it
- Pooled it
- Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity.European archives of psychiatry and clinical neuroscience · 2009Pooled it
- Treatment of Resistant Depression in Adolescents (TORDIA): week 24 outcomes.The American journal of psychiatry · 2010Trial
- Influence ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Neural signaling mechanisms in depression: bridging classical monoamine hypotheses, animal models, and emerging antidepressant strategies.Frontiers in cell and developmental biology · 2026Review
- Major depressive disorder: Validated treatments and future challenges.World journal of clinical cases · 2021Review
- Cost-Utility Analysis of Mindfulness-Based Cognitive Therapy Versus Antidepressant Pharmacotherapy for Prevention of Depressive Relapse in a Canadian Context: Analyse coût-utilité de la thérapie cognitive basée sur la pleine conscience contre la pharmacothérapie antidépressive pour prévenir la rechute de la dépression en contexte canadien.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2020Article
- A novel seizure quality index based on ictal parameters for optimizing clinical decision-making in electroconvulsive therapy. Part 2: Validation.European archives of psychiatry and clinical neuroscience · 2019Article
- [Psychotherapy of depressive disorders: Evidence in chronic depression and comorbidities].Der Nervenarzt · 2018Review
- The role of selective serotonin reuptake inhibitors in preventing relapse of major depressive disorder.Therapeutic advances in psychopharmacology · 2018Review
- Comparative effectiveness of dual-action versus single-action antidepressants for the treatment of depression in people living with HIV/AIDS.Journal of affective disorders · 2017Article
- Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2017Article
- Double-Blind Randomized Clinical Trial of the Efficacy of Venlafaxine Versus Citalopram in the Treatment of the Acute Phase of Major Depressive Disorder.Iranian journal of psychiatry and behavioral sciences · 2015Article
- Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.Bioorganic & medicinal chemistry · 2015Article
- Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics.Current neuropharmacology · 2015Review
- Behavioural screening of zebrafish using neuroactive traditional Chinese medicine prescriptions and biological targets.Scientific reports · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveMeta-analysis of all available trials of Venlafaxine in the treatment of major depressive disorders, including treatment resistant depression and long-term relapse prevention.
methodsWe conducted a meta-analysis comparing venlafaxine and tricyclics, or selective serotonin reuptake inhibitors (SSRIs), in major depression. We also included trials comparing venlafaxine and alternative antidepressants in subjects with treatment resistant depression, or compared with placebo in long-term relapse prevention. Trials were identified through searches of Medline, Embase, Cochrane Library and through accessing unpublished trials held by the manufacturer. Results based on intention to treat analyses where available, were pooled using theoretically exact conditional maximum likelihood methods for fixed effects (primary analyses), and numerical simulation using a Gibbs sampler for full random effects.
resultsCompared to all SSRIs for the treatment of major depression (fluoxetine, paroxetine, sertraline, citalopram, escitalopram and fluvoxamine), venlafaxine was associated with a greater response [odds ratio 1.15 (95% CI 1.02-1.29)] and remission [odds ratio 1.19 (95% CI 1.06-1.34)]. Overall drop out rates appeared similar for SSRIs and venlafaxine. Compared to tricyclics, response to venlafaxine was estimated to be greater by exact method, odds ratio 1.21 (95% CI 1.03-1.43), but not statistically significantly different, using a full random effects method odds ratio 1.22 (95% CI 0.96-1.54). We observed no difference in remission rates (odds ratio 1.06 (95% CI 0.74-1.63)). Tricyclics were less well tolerated with higher overall drop out rates. Compared to alternative antidepressants in treatment resistant depression (trials included comparison with sertraline, bupropion, fluoxetine, citalopram, and one with a range of agents-mostly SSRIs), the odds ratio for response was 1.35 (95% CI 1.19-1.54). The odds ratio for remission was 1.35 (95% CI 1.20-1.52). Compared to placebo the odds ratio for relapse prevention with venlafaxine was 0.37 (95% CI 0.27-0.51).
conclusionThis meta analysis provides evidence of the clinical efficacy of venlafaxine in achieving therapeutic response and remission in patients with major depression. Venlafaxine appears more effective than SSRIs, and at least as effective as tricyclic antidepressants, in the treatment of major depressive episode. Venlafaxine appeared more effective than comparators in treatment resistant depression. In addition, venlafaxine effective in reducing relapse when given long term after major depressive episode.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.